To corroborate the known ability of TAM receptors to regulate inflammatory processes in RA, we next assessed the potential clinical implications of pre-treatment expression of Axl/MerTK in the synovium of patients in whom TNF inhibitors were ineffective about to receive either rituximab (RTX) or tocilizumab (TOC). Here, MERTK is linked to rheumatoid arthritis.